Decentralized Clinical Trials Give Infectious Disease Studies the Flexibility and Speed They Need
What can we learn from the experiences of COVID-19 vaccine developers and clinical trial sponsors as we devise practical solutions for future development? Their successes showed us how eSource technology enables clinical trials to run more efficiently at a lower cost, with less burden on patients and sites.
In this article on page 37 for the Association of Clinical Research Professionals (ACRP) (Clinical Researcher), Clinical Ink Chief Strategy Officer Jonathan Andrus discusses how capturing data directly into the digital record using ePRO, eCOA, and similar assessments shortens timelines by months. And for infectious disease studies, where every minute matters, time saved allows sponsors to get necessary treatments to patients worldwide faster (and gives them an edge over the competition).